Engflag

Beta-Cardone

Quick links to important sections

Beta-Cardone

Beta-Cardone_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Beta-Cardone

What is Beta-Cardone? (Overview)

Property Description
Active Ingredient Sotalol Hydrochloride
Form Tablet, Oral Solution, Intravenous Solution
Pharmacological Class Antiarrhythmic Drug (Class II and Class III)
General Purpose Stabilizes heart rhythm
Origin Synthetic (Methanesulfonanilide)

Beta-Cardone is a widely recognized brand name for the prescription medicine containing the core active substance, Sotalol Hydrochloride (Sotalol or Sotalol HCl). This compound is a synthetic chemical entity derived from the methanesulfonanilide class. As a single product, it is available for oral administration as a tablet or oral solution, in addition to an intravenous solution used in specialized clinical settings. The active ingredient is formulated as a racemic mixture of two mirror-image forms, d-sotalol and l-sotalol, which is fundamental to its complete therapeutic profile.

Sotalol is classified as an antiarrhythmic drug due to its unique dual mechanism of action, a property that is clinically recognized by major cardiology institutions for managing electrical instability in the heart. This dual nature places it in the Vaughan Williams classification system as both a non-selective beta-blocker (Class II activity) and a selective potassium channel blocker (Class III activity). The Class II activity helps moderate the stimulating influence of stress hormones on the heart, while the Class III aspect primarily influences the timing of the heart's electrical recovery period.

The general purpose of Beta-Cardone is to help restore and maintain the heart's stable electrical pattern, a key objective in cardiac care. By combining the effects of slowing the heart rate and extending the time required for cardiac muscle cells to electrically recover, Sotalol directly contributes to rhythm stability. This combined approach is a distinctive feature, ensuring the heart maintains a sustained, steady beat.

Regulatory References

  1. Sotalol - StatPearls (NIH)

What side effects are possible with Beta-Cardone?

Possible side effects and safety information

The official safety profile for Sotalol Hydrochloride (Beta-Cardone) is structured around two main categories of risk, as documented in regulatory sources like the FDA and EMA. The most frequent adverse reactions relate to its beta-blocker (Class II) activity, while the most serious risks stem from its potassium channel-blocking (Class III) activity.

Adverse Reaction Frequencies

Adverse reactions are classified by frequency based on clinical trial data and post-marketing surveillance:

Classification Examples of Officially Listed Adverse Reactions
Very Common (≥10%) Fatigue, Dizziness, Asthenia (General Weakness), Lightheadedness
Common (1% to <10%) Bradycardia (Slow Heart Rate), Dyspnea (Shortness of Breath), Headache, Nausea, Hypotension, Diarrhea, Insomnia

Serious adverse reactions officially documented in labeling include life-threatening proarrhythmia, primarily Torsade de Pointes (TdP), worsening of Heart Failure, and severe Bradycardia or AV Block.

Time- and Population-Related Safety Notes

The risk of Proarrhythmia is highest during the initiation of therapy and following every upward dose adjustment, as specified in regulatory documents. Safety labeling also mandates specific considerations for certain groups.

  • Renal Impairment: Patients with reduced kidney function are at increased risk of drug accumulation, necessitating careful monitoring or contraindication below specific creatinine clearance thresholds.
  • Other Constraints: The medicine is strictly restricted from use in patients with pre-existing conditions such as Long QT Syndromes, uncontrolled Heart Failure, or Hypokalemia, as these increase the serious cardiac risk.

Overdose and Emergency Response

A Sotalol Hydrochloride (Beta-Cardone) overdosage may lead to severe clinical presentations, defined by regulatory authorities as a severe extension of the drug's intended effects. Documented overdose manifestations include profound bradycardia, hypotension, congestive heart failure, bronchospasm, and hypoglycemia, which reflect the affected physiological systems.

When to Seek Urgent Help

Regulators explicitly state that immediate medical attention is mandated for any suspected overdosage. Emergency services must be contacted immediately if a person exhibits signs of life-threatening events, such as collapse, seizure, severe difficulty breathing, or loss of consciousness. These severe outcomes are officially classified as potentially life-threatening and include Torsade de Pointes (TdP), Cardiac Asystole, and advanced Heart Block. Overdosage, whether accidental or intentional, has been officially documented to result in death.

Official Management Statements

Official labeling describes the management approach as entirely symptomatic and supportive, as no specific pharmacological antidote is listed. Procedures documented in prescribing information include transvenous cardiac pacing and DC cardioversion for TdP, and the use of agents like Atropine or Epinephrine to manage acute cardiovascular symptoms. Patients with pre-existing kidney injury face an elevated risk of severe outcomes due to impaired drug clearance, a factor noted in official labeling alongside the risk posed by electrolyte imbalances.

Therapeutic Uses of Beta-Cardone

Beta-Cardone is relevant in clinical settings for managing heart rhythm disorders, addressing conditions where symptoms create noticeable physiological strain. The medication is commonly used to help with therapeutic goals related to two major clinical domains.

Management of Rhythms Associated with Severe Ventricular Presentations

Beta-Cardone is applied across domains where additional symptomatic support is needed to address rhythm disorders associated with severe clinical presentations, such as sustained ventricular tachycardia. This medication plays a role in managing these rhythm disturbances and contributes to easing symptoms related to heightened physiological activity in patients where symptoms create noticeable physiological strain. Its main uses are addressing severe ventricular arrhythmias and for rhythm maintenance in highly symptomatic atrial fibrillation or atrial flutter.

Rhythm Management for Highly Symptomatic Atrial Fibrillation and Flutter

This medication is generally used to help support rhythm management over the long term, with the goal of supporting sustained, regular heart function in patients who have a history of highly symptomatic episodes. This supports easing associated symptom clusters, such as palpitations, lightheadedness, and fatigue. It is applied in scenarios where Tachyarrhythmia-Related Discomfort (such as palpitations and chest fluttering) causes noticeable functional strain. The treatment is often reserved for these highly symptomatic, disruptive presentations.

Quick Fact: Relief for Symptomatic Burden
Assists with maintaining functional stability during episodes of highly symptomatic atrial fibrillation/flutter.

Eligibility and Restrictions for Use

Official Population Eligibility for Beta-Cardone

Populations Allowed: Beta-Cardone is officially approved for use in adults with documented life-threatening ventricular arrhythmias, and for rhythm maintenance in highly symptomatic atrial fibrillation or atrial flutter. Pediatric use is established for life-threatening arrhythmias under specific, monitored protocols.

Absolute Contraindications (Must Not Use): Regulatory labels strictly prohibit use in patients with pre-existing cardiac electrical instability, including sinus bradycardia (heart rate less than 50 bpm), second or third-degree AV block without a pacemaker, or congenital/acquired long QT syndrome. It is also contraindicated in cardiogenic shock, decompensated heart failure (NYHA Class IV), bronchial asthma, and uncorrected hypokalemia or hypomagnesemia.

Condition-Based Restrictions: Eligibility is restricted by kidney function. Use is officially contraindicated for atrial fibrillation/flutter patients with a creatinine clearance below 40 mL/min. Older adults require cautious use due to the increased prevalence of reduced renal function. Use in pregnancy is restricted to cases where the benefit outweighs potential risk, and official labeling advises against breastfeeding.

What should I know about interactions with other medicines?

Beta-Cardone Interactions with Other Medicines and Products

The interaction profile of Beta-Cardone (Sotalol Hydrochloride) is determined by its ability to prolong the QT interval and exert a beta-blocking effect, as documented in regulatory prescribing information.

Formal Interaction Restrictions

Interaction Type Examples and Requirement Regulatory Focus
Contraindicated Combinations Other QT-prolonging drugs (e.g., certain Class I/III antiarrhythmics, macrolides) are generally avoided due to the high risk of Torsades de Pointes (TdP). Additive TdP Risk
Pharmacodynamic Risk Co-administration with cardiodepressant agents like Verapamil or Diltiazem is advised against because of the potential for additive effects on heart rate and AV conduction. Additive Cardiodepression
Absorption Interference Aluminum- or magnesium-based antacids must be administered at least 2 hours before or 2 hours after Sotalol, as they reduce its serum concentration. Reduced Exposure

Other Documented Interactions

Beta-Cardone's beta-blocking activity may mask the early warning signs of hypoglycemia in patients taking insulin or oral antidiabetic drugs. Agents that cause hypokalaemia or hypomagnesaemia (such as certain diuretics) must be used with caution, as these electrolyte imbalances exaggerate the risk of QT prolongation and TdP. Sotalol should also be taken preferably 1–2 hours before meals to optimize absorption, as food, especially dairy products, can interfere with its uptake.

Mechanism of Action

How Beta-Cardone Works

Blocking beta-Adrenergic Receptor Signals

This domain covers the primary molecular action: Beta-Cardone is an antagonist that acts within domains involving receptor-mediated signaling by binding to beta-adrenergic receptors. This physically blocks the binding site for the body's natural activators, such as epinephrine (adrenaline) and norepinephrine, thereby modifying early molecular steps that modulate systemic physiological function.

Dampening Sympathetic Signal Cascades

Beta-Cardone engages mechanisms that act on processes characterized by heightened sympathetic input driven by the sympathetic nervous system (SNS). The drug modifies the intracellular mechanistic cascade by limiting the production of the second messenger, cyclic AMP (cAMP), which results in the suppression of downstream signaling sequences. This effect is relevant in systems where targeted pathway adjustment is required to result in a modulation of activity within targeted pathways.

Modulating Cardiac Autonomic Control

This domain describes the resulting physiological consequences of the receptor blockade on the heart and vasculature. By limiting the stimulatory input from catecholamines, the mechanism influences pathways associated with heightened physiological responses, resulting in a reduction of cardiac sympathetic activity. This action is achieved by inducing negative chronotropy (slower heart rate) and negative inotropy (reduced force of contraction), resulting in physiological adjustments linked to the mechanism of action.

Dosage and Administration Information

How to Use Beta-Cardone: Administration Guidelines

Beta-Cardone, containing Sotalol Hydrochloride, is used according to a structured protocol to ensure precise administration.

Parameter Administration Rule
Route of Administration Oral (tablets or solution) and Intravenous (IV) infusion are the available routes.
Adult Dosing Schedule Initial oral dose is 80 mg twice daily (160 mg total daily dose). The typical maintenance range is 160 mg to 320 mg/day in two divided doses. Doses are increased in increments of 80 mg/day, allowing 2 to 3 days between adjustments.
Administration Timing Oral doses are taken 1 to 2 hours before meals (on an empty stomach) to minimize potential effects on absorption.
Special Condition: Initiation Therapy is initiated or re-initiated in a facility capable of cardiac resuscitation and continuous ECG monitoring for a minimum of three days on the maintenance dose. Serum potassium and magnesium levels are measured and normalized prior to starting.
Population Rule: Renal Function Since the medicine is primarily excreted by the kidneys, the dosing interval is extended for patients with decreased kidney function. For example, a creatinine clearance of 30-59 mL/min requires the interval to be increased to 24 hours. No dosage adjustment is required for hepatic impairment.
Missed Dose Rule If a dose is missed, the next dose is taken at the usual time; do not double the dose or shorten the dosing interval.

The overall use protocol involves controlled monitoring during the start of therapy and subsequent dose increases, which are separated by several days to attain a stable level. For long-term use, gradual dose reduction over one to two weeks is utilized if the medicine is discontinued.

Recent Clinical Evidence

Research evidence / Overview of studies for Beta-Cardone

Beta-Cardone (Sotalol) was studied in organized clinical trials and systematic reviews to assess its role in regulating heart rhythm. The evidence base is categorized according to the specific heart conditions for which it was evaluated, focusing on controlled studies that measure changes in the heart's electrical activity and the recurrence of disruptive episodes.

Evidence for Documented Life-Threatening Ventricular Arrhythmias

Research exploring the use of this medicine for life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia (VT) and ventricular fibrillation (VF), included controlled trials. These studies were applied in studies examining patient-reported experiences among adult populations who had previously experienced a serious ventricular event. Research examined outcomes related to the reduction of inducible heart rhythm disturbances during specialized testing and tracked the subsequent frequency of arrhythmia recurrence.

Findings from the research describe patterns observed in these studies, with some trials reporting that one of the studied outcomes, arrhythmia recurrence, occurred less frequently in the sotalol cohorts when compared to other antiarrhythmic drugs that were evaluated in the same trial. Data from another large trial reported the drug did not produce a statistically significant increase in overall survival when compared to a placebo in patients following a myocardial infarction (heart attack).

Evidence for Highly Symptomatic Atrial Fibrillation and Flutter

Research exploring the use of Beta-Cardone for conditions characterized by fluctuating or episodic manifestations, such as highly symptomatic atrial fibrillation and atrial flutter (AFIB/AFL), primarily involved Randomized Controlled Trials (RCTs) and systematic reviews. These studies were designed to evaluate the medicine's role in maintaining normal sinus rhythm after the patient had been converted back to a regular rhythm.

Findings describe patterns observed in the studies, where multiple RCTs reported that the proportion of patients who continued to be in a regular heart rhythm was greater in the sotalol cohorts when compared to the placebo cohorts. When compared to other antiarrhythmic drugs, some meta-analyses reported that findings concerning the recurrence rate were mixed when comparing the drug to certain other agents. The durability of the effect is finite, as studies observe the high natural recurrence rate of AFIB/AFL.

Key Study Limitations and Research Gaps

A major limitation noted across the research is the absence of data showing enhanced long-term survival in patients with life-threatening ventricular arrhythmias. Follow-up durations were limited in the atrial arrhythmia trials, focusing on short-term changes, meaning long-term outcomes are not fully characterized. Data for certain groups, such as children and specific comorbidity-defined subgroups, remain insufficient. The research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

  1. PRODUCT MONOGRAPH MYLAN-SOTALOL (sotalol hydrochloride, BP) Tablets (Reference for follow-up durations)

Frequently Asked Questions (FAQ)

Common questions about Beta-Cardone (FAQ)

Q: What is Beta-Cardone and what is it used for?

Beta-Cardone is the brand name for the medicine sotalol, which belongs to a class of drugs called beta-blockers. It is also a medication that works on the electrical activity of the heart.

It is primarily used to:

  • Treat certain types of fast or irregular heart rhythms (arrhythmias), such as atrial fibrillation or atrial flutter.
  • Manage life-threatening irregular heart rhythms that come from the lower chambers of the heart (ventricles), known as ventricular arrhythmias.

Beta-Cardone works by slowing down the electrical signals in the heart to help the heart beat more slowly and in a more regular rhythm.

Q: What are the most common side effects of Beta-Cardone?

Like all medicines, Beta-Cardone can cause side effects. The most common side effects often include:

  • Fatigue or feeling unusually tired
  • Dizziness or lightheadedness
  • Slow heartbeat (bradycardia)
  • Shortness of breath
  • Nausea or vomiting
  • Headache
  • Feeling the heart beat hard, fast, or irregularly (palpitations)

It is important to discuss any side effects you experience with your healthcare provider.

Q: Can I suddenly stop taking Beta-Cardone?

No, you should not stop taking Beta-Cardone suddenly. Stopping this medication abruptly can be dangerous, especially for people with heart disease.

Suddenly stopping the medicine can lead to serious heart problems, such as a worsening of chest pain or a life-threatening change in heart rhythm. Your healthcare provider will give you specific instructions on how to safely decrease your dose gradually if the medication needs to be stopped.

Q: What should I tell my doctor before starting Beta-Cardone?

Before starting Beta-Cardone, you must tell your healthcare provider about all your medical conditions and all the medications, vitamins, and supplements you take.

It is especially important to inform your doctor if you have or have had:

  • Asthma or other lung or breathing problems, such as chronic obstructive pulmonary disease (COPD).
  • Heart problems other than the one being treated, such as severe heart failure, certain types of heart block, or Long QT syndrome.
  • Kidney disease, as this medication is removed from the body through the kidneys.
  • Low blood pressure.
  • Diabetes.
  • Low levels of potassium or magnesium in your blood.
  • Are pregnant or plan to become pregnant.
  • Are breastfeeding, as the medicine can pass into breast milk.

Your doctor will need this information to ensure Beta-Cardone is safe and appropriate for you.

Q: Does Beta-Cardone interact with any other medications?

Yes, Beta-Cardone can interact with many other medications, which may change how it works or increase the risk of serious side effects.

Do not take Beta-Cardone with any medicine that can prolong the QT interval (a measure of electrical activity in the heart), as this greatly increases the risk of a dangerous heart rhythm called torsade de pointes. Examples of these interacting drugs include some other anti-arrhythmic drugs, certain antibiotics, and some medicines for mental health conditions.

Beta-Cardone can also interact with other drugs that lower heart rate or blood pressure, such as certain calcium channel blockers. It is essential to provide your doctor with a complete list of all the drugs you are taking.

How should Beta-Cardone be stored and disposed of?

Official Storage and Disposal Instructions

Official regulatory documents define the required conditions for storing and disposing of Sotalol (Beta-Cardone) to maintain stability and safety.

Requirement Instructions
Storage Conditions Store the tablet form in its original package to protect from light.
Stability The solution for injection is stable for up to 36 months.
Handling (Injectables) Inspect the solution for injection visually for particulate matter and discoloration before use.
Child Safety Keep the sharps disposal container out of the reach of children (for injectable forms).
Disposal of Sharps Do not throw away used syringes and needles in household trash or recycling. Disposal must follow community guidelines for hazardous waste.

These mandated rules ensure the product remains effective over its shelf-life and that all associated medical waste is handled safely.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Beta-Cardone found in:

A-Z Index: